Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Barcelona, Spain, 30 August: Diabetes mellitus-associated coronary artery disease (CAD) is assuming epidemic proportions, especially in western countries. Both coronary revascularization and medical management have improved tremendously over the last decade and the respective role in the diabetic population is not well defined. This aspect was investigated in the BARI 2D study*.
The results of the BARI 2D trial demonstrate that diabetic patients with stable CAD need more than just stents or grafts, namely a global care including, in addition to coronary revascularization, aggressive cardiovascular risk factor management and life style changes. In the presence of an excellent compliance, a strategy based on initial medical management followed by coronary revascularization if clinically indicated is a good option for diabetic patients with stable CAD.
A total of 2368 diabetic patients with stable CAD and qualifying for coronary revascularization were randomized to optimal medical therapy or revascularisation − either with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) − in addition to optimal medical therapy. Primary end points of the study were the 5-.year rate of death and major cardiovascular invents (MACE) defined as a composite of death, myocardial infarction or stroke. Survival and MACE-free survival at follow-up did not differ between the revascularisation group and the medical therapy group. At 5 years, 42% of the patients randomised to medical management did require coronary revascularisation. Both groups were characterized by an excellent compliance with respect to medical therapy. - Ends -
*Published on June 11th 2009 in the New England Journal of Medicine.
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2009. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology.
© 2017 European Society of Cardiology. All rights reserved